Oncotrack - methods for systematic next generation oncology biomarker development

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: Oncotrack - methods for systematic next generation oncology biomarker development
Project Number: CORDIS-203695
Project web address: Follow on CORDIS
Organization: Bayer Pharma Ag, Germany, Berlin
Collaborators: Uppsala University, SE
Stockholm University, SE
University College London, GB
Charité Universität Medicine, DE
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Ev, DE
Janssen Pharmaceutica N.V., BE
Universite Paris-Sud, FR
F. Hoffmann - La Roche Ltd., CH
Pfizer Ltd, GB
Eli Lilly Company Limited, GB
Technische Universitaet Dresden, DE
Merck Kommanditgesellschaft Auf Aktien, DE
Astra Zeneca Ab, SE
Medizinische Universitat Graz, AT
Experimental Pharmacology & Oncology Berlin-Buch Gmbh, DE
Gabo:Mi Gesellschaft Für Ablauforganisation :Milliarium Mbh & Co. Kg, DE
International Prevention Research Institute Sas, FR
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron, ES
Boehriger Ingelheim International Gmbh, DE
Dahlem Centre For Genome Research And Medical Systems Biology, DE
Alacris Theranostics Gmbh, DE
Principal Investigators (PI): Greta Borg-Carbott, GB
Birgit Fuchs, DE
Sven Kreigenfeld, DE
Ann Nielsen, SE
Nicolas Lecompte, FR
Eveline Fräßdorf, DE
Margareta Uvhagen Antoni, SE
Eva Lindgren, SE
Birgit Steckel-Hamann, GB
Jason Hannon, CH
Ninog Péresse, DE
Henk Sipma, BE
Erik Patzelt, DE
Ingrid Stark, DE
Ralf Sudbrak, DE
Anke Badrow, DE
Jens Hoffmann, DE
Alejandro Piris, ES
Elisabeth Marchi, FR
Janet Jarrett, GB
Johannes Haybaeck, AT
David Henderson, DE
 
Project Description:
We propose here an exhaustive analysis of the genome, exome, methylome and transcriptome of primary tumours and metastases from patients with colon carcinoma, based on a combination of deep sequencing and chip based techniques. Dependent on their availability, we shall also perform analyses of tumor stem cells, circulating tumor cells, free tumor DNA in serum and xenografts derived from the same patients. This will be complemented by the development and application of highly sensitive techniques to identify individual mutations, transcripts and proteins/protein complexes both in-situ in pathology slides as well as in patients’ blood or serum. The integration of these results will allow us to address the heterogeneity of the tumor samples, to deduce the genome/epigenome/transcriptome of the different cell types making up or originating from the tumor (e.g. circulating tumor cells, tumour stem cells or xenografts), to establish models able to predict suitable candidates for further biomarker development, and also to predict the effects and side effects of drugs in the treatment of genetically defined groups of patients. Available biomarkers, as well as biomarkers predicted from the work within the project will be validated in patient derived xenograft models and stem cell cultures, and ultimately transferred into a point of care (POC) diagnostic format. In parallel we will explore the use of the global genome and methylome information, e.g. derived from the analysis of free tumor DNA in the serum of the patient, as the ‘ultimate’ biomarker, to model the biology of the tumor (possibly even before any tumor has been localised), and as an independent route to predict clinically relevant parameters. Though sequencing/methylation analysis of the genome of the tumor through free DNA is currently still too costly for use as a routine diagnostic, this is likely to change over the period covered by the grant, due to the extremely rapid progress in the development of large scale sequencing techniques.
 
Project Terms:
There are no related terms in database.
Project Title: Oncotrack - methods for systematic next generation oncology biomarker development
Project Number: CORDIS-203695
Project web address: Follow on CORDIS
Organization: Bayer Pharma Ag, Germany, Berlin
Collaborators: Uppsala University, SE
Stockholm University, SE
University College London, GB
Charité Universität Medicine, DE
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Ev, DE
Janssen Pharmaceutica N.V., BE
Universite Paris-Sud, FR
F. Hoffmann - La Roche Ltd., CH
Pfizer Ltd, GB
Eli Lilly Company Limited, GB
Technische Universitaet Dresden, DE
Merck Kommanditgesellschaft Auf Aktien, DE
Astra Zeneca Ab, SE
Medizinische Universitat Graz, AT
Experimental Pharmacology & Oncology Berlin-Buch Gmbh, DE
Gabo:Mi Gesellschaft Für Ablauforganisation :Milliarium Mbh & Co. Kg, DE
International Prevention Research Institute Sas, FR
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron, ES
Boehriger Ingelheim International Gmbh, DE
Dahlem Centre For Genome Research And Medical Systems Biology, DE
Alacris Theranostics Gmbh, DE
Principal Investigators (PI): Greta Borg-Carbott, GB
Birgit Fuchs, DE
Sven Kreigenfeld, DE
Ann Nielsen, SE
Nicolas Lecompte, FR
Eveline Fräßdorf, DE
Margareta Uvhagen Antoni, SE
Eva Lindgren, SE
Birgit Steckel-Hamann, GB
Jason Hannon, CH
Ninog Péresse, DE
Henk Sipma, BE
Erik Patzelt, DE
Ingrid Stark, DE
Ralf Sudbrak, DE
Anke Badrow, DE
Jens Hoffmann, DE
Alejandro Piris, ES
Elisabeth Marchi, FR
Janet Jarrett, GB
Johannes Haybaeck, AT
David Henderson, DE
 
Project Categories:
Natural Sciences > Aging-related markers and targets > Biomarkers of diseases
 
Other Information:
Fiscal Year: 2011
Project Start Date: 1 January 2010
Project End Date: 31 December 2016
Project program: FP7-JTI
 
Project Funding Information:
Funding Mechanism: JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)
Year Funding Organization Total Funding, $
2011 European Research Council $34,682,139
Project Title: Oncotrack - methods for systematic next generation oncology biomarker development
Project Number: CORDIS-203695
Project web address: Follow on CORDIS
Organization: Bayer Pharma Ag, Germany, Berlin
Collaborators: Uppsala University, SE
Stockholm University, SE
University College London, GB
Charité Universität Medicine, DE
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Ev, DE
Janssen Pharmaceutica N.V., BE
Universite Paris-Sud, FR
F. Hoffmann - La Roche Ltd., CH
Pfizer Ltd, GB
Eli Lilly Company Limited, GB
Technische Universitaet Dresden, DE
Merck Kommanditgesellschaft Auf Aktien, DE
Astra Zeneca Ab, SE
Medizinische Universitat Graz, AT
Experimental Pharmacology & Oncology Berlin-Buch Gmbh, DE
Gabo:Mi Gesellschaft Für Ablauforganisation :Milliarium Mbh & Co. Kg, DE
International Prevention Research Institute Sas, FR
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron, ES
Boehriger Ingelheim International Gmbh, DE
Dahlem Centre For Genome Research And Medical Systems Biology, DE
Alacris Theranostics Gmbh, DE
Principal Investigators (PI): Greta Borg-Carbott, GB
Birgit Fuchs, DE
Sven Kreigenfeld, DE
Ann Nielsen, SE
Nicolas Lecompte, FR
Eveline Fräßdorf, DE
Margareta Uvhagen Antoni, SE
Eva Lindgren, SE
Birgit Steckel-Hamann, GB
Jason Hannon, CH
Ninog Péresse, DE
Henk Sipma, BE
Erik Patzelt, DE
Ingrid Stark, DE
Ralf Sudbrak, DE
Anke Badrow, DE
Jens Hoffmann, DE
Alejandro Piris, ES
Elisabeth Marchi, FR
Janet Jarrett, GB
Johannes Haybaeck, AT
David Henderson, DE
 
Title FY Funding
There are no results for this project in database.
Project Title: Oncotrack - methods for systematic next generation oncology biomarker development
Project Number: CORDIS-203695
Project web address: Follow on CORDIS
Organization: Bayer Pharma Ag, Germany, Berlin
Collaborators: Uppsala University, SE
Stockholm University, SE
University College London, GB
Charité Universität Medicine, DE
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Ev, DE
Janssen Pharmaceutica N.V., BE
Universite Paris-Sud, FR
F. Hoffmann - La Roche Ltd., CH
Pfizer Ltd, GB
Eli Lilly Company Limited, GB
Technische Universitaet Dresden, DE
Merck Kommanditgesellschaft Auf Aktien, DE
Astra Zeneca Ab, SE
Medizinische Universitat Graz, AT
Experimental Pharmacology & Oncology Berlin-Buch Gmbh, DE
Gabo:Mi Gesellschaft Für Ablauforganisation :Milliarium Mbh & Co. Kg, DE
International Prevention Research Institute Sas, FR
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron, ES
Boehriger Ingelheim International Gmbh, DE
Dahlem Centre For Genome Research And Medical Systems Biology, DE
Alacris Theranostics Gmbh, DE
Principal Investigators (PI): Greta Borg-Carbott, GB
Birgit Fuchs, DE
Sven Kreigenfeld, DE
Ann Nielsen, SE
Nicolas Lecompte, FR
Eveline Fräßdorf, DE
Margareta Uvhagen Antoni, SE
Eva Lindgren, SE
Birgit Steckel-Hamann, GB
Jason Hannon, CH
Ninog Péresse, DE
Henk Sipma, BE
Erik Patzelt, DE
Ingrid Stark, DE
Ralf Sudbrak, DE
Anke Badrow, DE
Jens Hoffmann, DE
Alejandro Piris, ES
Elisabeth Marchi, FR
Janet Jarrett, GB
Johannes Haybaeck, AT
David Henderson, DE
 
Project Title Organization FY Funding
Oncotrack - Methods For Systematic Next Generation Oncology Biomarker DevelopmentBayer Pharma Ag2011$34,682,139
Project Title: Oncotrack - methods for systematic next generation oncology biomarker development
Project Number: CORDIS-203695
Project web address: Follow on CORDIS
Organization: Bayer Pharma Ag, Germany, Berlin
Collaborators: Uppsala University, SE
Stockholm University, SE
University College London, GB
Charité Universität Medicine, DE
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Ev, DE
Janssen Pharmaceutica N.V., BE
Universite Paris-Sud, FR
F. Hoffmann - La Roche Ltd., CH
Pfizer Ltd, GB
Eli Lilly Company Limited, GB
Technische Universitaet Dresden, DE
Merck Kommanditgesellschaft Auf Aktien, DE
Astra Zeneca Ab, SE
Medizinische Universitat Graz, AT
Experimental Pharmacology & Oncology Berlin-Buch Gmbh, DE
Gabo:Mi Gesellschaft Für Ablauforganisation :Milliarium Mbh & Co. Kg, DE
International Prevention Research Institute Sas, FR
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron, ES
Boehriger Ingelheim International Gmbh, DE
Dahlem Centre For Genome Research And Medical Systems Biology, DE
Alacris Theranostics Gmbh, DE
Principal Investigators (PI): Greta Borg-Carbott, GB
Birgit Fuchs, DE
Sven Kreigenfeld, DE
Ann Nielsen, SE
Nicolas Lecompte, FR
Eveline Fräßdorf, DE
Margareta Uvhagen Antoni, SE
Eva Lindgren, SE
Birgit Steckel-Hamann, GB
Jason Hannon, CH
Ninog Péresse, DE
Henk Sipma, BE
Erik Patzelt, DE
Ingrid Stark, DE
Ralf Sudbrak, DE
Anke Badrow, DE
Jens Hoffmann, DE
Alejandro Piris, ES
Elisabeth Marchi, FR
Janet Jarrett, GB
Johannes Haybaeck, AT
David Henderson, DE
 
Project number Project title Principal investigator
There are no any related projects.
Project Title: Oncotrack - methods for systematic next generation oncology biomarker development
Project Number: CORDIS-203695
Project web address: Follow on CORDIS
Organization: Bayer Pharma Ag, Germany, Berlin
Collaborators: Uppsala University, SE
Stockholm University, SE
University College London, GB
Charité Universität Medicine, DE
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Ev, DE
Janssen Pharmaceutica N.V., BE
Universite Paris-Sud, FR
F. Hoffmann - La Roche Ltd., CH
Pfizer Ltd, GB
Eli Lilly Company Limited, GB
Technische Universitaet Dresden, DE
Merck Kommanditgesellschaft Auf Aktien, DE
Astra Zeneca Ab, SE
Medizinische Universitat Graz, AT
Experimental Pharmacology & Oncology Berlin-Buch Gmbh, DE
Gabo:Mi Gesellschaft Für Ablauforganisation :Milliarium Mbh & Co. Kg, DE
International Prevention Research Institute Sas, FR
Fundacio Privada Institut D'Investigacio Oncologica De Vall-Hebron, ES
Boehriger Ingelheim International Gmbh, DE
Dahlem Centre For Genome Research And Medical Systems Biology, DE
Alacris Theranostics Gmbh, DE
Principal Investigators (PI): Greta Borg-Carbott, GB
Birgit Fuchs, DE
Sven Kreigenfeld, DE
Ann Nielsen, SE
Nicolas Lecompte, FR
Eveline Fräßdorf, DE
Margareta Uvhagen Antoni, SE
Eva Lindgren, SE
Birgit Steckel-Hamann, GB
Jason Hannon, CH
Ninog Péresse, DE
Henk Sipma, BE
Erik Patzelt, DE
Ingrid Stark, DE
Ralf Sudbrak, DE
Anke Badrow, DE
Jens Hoffmann, DE
Alejandro Piris, ES
Elisabeth Marchi, FR
Janet Jarrett, GB
Johannes Haybaeck, AT
David Henderson, DE
 
Title Journal Year Country Rel